MSD to takeover Takeda's Dunboyne facility Pharmaceutical firm MSD has agreed to acquire Takeda's manufacturing facility in Dunboyne, Co Meath as a going concern. Business • 07 Aug 20
MSD to takeover Takeda's Dunboyne facility Pharmaceutical firm MSD has agreed to acquire Takeda's manufacturing facility in Dunboyne, Co Meath as a going concern. Business • 07 Aug 20
Dealmakers brace for slowdown after strong year of M&A Dealmakers celebrating their third-strongest year on record are fretting 2019 will herald a steep drop in mergers and acquisitions worldwide, as market jitters and economic uncertainty take their toll. Business • 21 Dec 18
Dealmakers brace for slowdown after strong year of M&A Dealmakers celebrating their third-strongest year on record are fretting 2019 will herald a steep drop in mergers and acquisitions worldwide, as market jitters and economic uncertainty take their toll. Business • 21 Dec 18
Takeda shareholders approve $59 billion Shire deal Takeda Pharmaceutical shareholders have approved the company's $59 billion takeover of London-listed Shire. Business • 05 Dec 18
Takeda shareholders approve $59 billion Shire deal Takeda Pharmaceutical shareholders have approved the company's $59 billion takeover of London-listed Shire. Business • 05 Dec 18
Takeda gets key US regulatory approval to buy Shire Japan's Takeda Pharmaceutical has received a key US regulatory approval for its $62 billion deal to buy London-listed Shire. Business • 10 Jul 18
Takeda gets key US regulatory approval to buy Shire Japan's Takeda Pharmaceutical has received a key US regulatory approval for its $62 billion deal to buy London-listed Shire. Business • 10 Jul 18
Return of mega-deals helps European M&A double A resurgence in mega-deals has led to a doubling of mergers and acquisitions activity in Europe so far this year, raising questions among bankers and lawyers about when the pace of blockbuster transactions will start to fade. Business • 29 Jun 18
Return of mega-deals helps European M&A double A resurgence in mega-deals has led to a doubling of mergers and acquisitions activity in Europe so far this year, raising questions among bankers and lawyers about when the pace of blockbuster transactions will start to fade. Business • 29 Jun 18
Japan's Takeda agrees €51 billion takeover of Shire Takeda Pharmaceutical has agreed to buy London-listed Shire for £45.3 billion pounds (€51.5 billion) after the Japanese company raised the amount of cash in its offer to $30.33 to secure a recommendation. Business • 08 May 18
Japan's Takeda agrees €51 billion takeover of Shire Takeda Pharmaceutical has agreed to buy London-listed Shire for £45.3 billion pounds (€51.5 billion) after the Japanese company raised the amount of cash in its offer to $30.33 to secure a recommendation. Business • 08 May 18
Shire grows earnings by 6%, but holds cautious outlook Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, today reported a 6% rise in first-quarter earnings. Business • 26 Apr 18
Shire grows earnings by 6%, but holds cautious outlook Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, today reported a 6% rise in first-quarter earnings. Business • 26 Apr 18
Shire willing to recommend Takeda's $65 billion offer Rare disease drug maker Shire has said it is willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical to shareholders. Business • 25 Apr 18
Shire willing to recommend Takeda's $65 billion offer Rare disease drug maker Shire has said it is willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical to shareholders. Business • 25 Apr 18
Japan's Takeda nudges up Shire offer to £47 a share Japan's Takeda Pharmaceutical has increased its offer for Shire to $47 a share after its three previous bids - the last at £46.50 - were rejected by the rare-disease drugs specialist. Business • 20 Apr 18
Japan's Takeda nudges up Shire offer to £47 a share Japan's Takeda Pharmaceutical has increased its offer for Shire to $47 a share after its three previous bids - the last at £46.50 - were rejected by the rare-disease drugs specialist. Business • 20 Apr 18
Shire to sell oncology business to Servier Shire, the pharmaceutical company which specialises in rare diseases, said today it was selling its oncology business to French drug maker Servier for $2.4 billion. Business • 16 Apr 18
Shire to sell oncology business to Servier Shire, the pharmaceutical company which specialises in rare diseases, said today it was selling its oncology business to French drug maker Servier for $2.4 billion. Business • 16 Apr 18
Shire cuts its 2020 revenue targets Shire has ditched its revenue target of $20 billion by 2020 due to increased generic competition and new drugs from rivals. Business • 09 Jan 18
Shire cuts its 2020 revenue targets Shire has ditched its revenue target of $20 billion by 2020 due to increased generic competition and new drugs from rivals. Business • 09 Jan 18
Shire's third quarter results beat expectations Pharmaceutical firm Shire has reported a 20% rise in third-quarter earnings, beating market expectations, driven by growth in its immunology franchise. Business • 27 Oct 17
Shire's third quarter results beat expectations Pharmaceutical firm Shire has reported a 20% rise in third-quarter earnings, beating market expectations, driven by growth in its immunology franchise. Business • 27 Oct 17
Pharma firm to create 150 jobs at new Dublin office Pharmaceutical company Shire is to create 150 jobs at its new corporate offices in Ireland over the next few months. Ireland • 27 Apr 17
Pharma firm to create 150 jobs at new Dublin office Pharmaceutical company Shire is to create 150 jobs at its new corporate offices in Ireland over the next few months. Ireland • 27 Apr 17
Shire jumps as Vyvanse drug helps it beat forecast Strong demand for Shire's top-selling Vyvanse drug helped to lift first-quarter earnings by a better than expected 12%. Business • 29 Apr 16
Shire jumps as Vyvanse drug helps it beat forecast Strong demand for Shire's top-selling Vyvanse drug helped to lift first-quarter earnings by a better than expected 12%. Business • 29 Apr 16
Shire to buy Baxalta for $32 billion Shire clinched its six-month pursuit of Baxalta International today with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. Business • 11 Jan 16
Shire to buy Baxalta for $32 billion Shire clinched its six-month pursuit of Baxalta International today with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. Business • 11 Jan 16
Shire goes public on $30bn bid for Baxalta Pharmaceutical group Shire said it was seeking to buy Baxalta in a $30 billion all-share deal, going public with its bid to create a global specialist in rare diseases after the US firm spurned its initial approach. Business • 04 Aug 15
Shire goes public on $30bn bid for Baxalta Pharmaceutical group Shire said it was seeking to buy Baxalta in a $30 billion all-share deal, going public with its bid to create a global specialist in rare diseases after the US firm spurned its initial approach. Business • 04 Aug 15
AbbVie beats estimates on higher Humira sales US drugmaker AbbVie today reported a better than expected quarterly adjusted profit due to higher sales of its autoimmune disease drug Humira. Business • 30 Jan 15
AbbVie beats estimates on higher Humira sales US drugmaker AbbVie today reported a better than expected quarterly adjusted profit due to higher sales of its autoimmune disease drug Humira. Business • 30 Jan 15
Shire to buy NPS for $5.2 billion Shire has agreed to buy NPS Pharmaceuticals for $5.2 billion in its biggest acquisition yet. Business • 12 Jan 15
Shire to buy NPS for $5.2 billion Shire has agreed to buy NPS Pharmaceuticals for $5.2 billion in its biggest acquisition yet. Business • 12 Jan 15
Shire raises guidance again after Q3 earnings jump Pharmaceutical firm Shire has today raised its guidance for full-year earnings. Business • 24 Oct 14
Shire raises guidance again after Q3 earnings jump Pharmaceutical firm Shire has today raised its guidance for full-year earnings. Business • 24 Oct 14
Shire's interim CFO James Bowling leaves firm Drugs firm Shire has announced that interim chief financial officer James Bowling has resigned after ten years with the firm. Business • 20 Oct 14
Shire's interim CFO James Bowling leaves firm Drugs firm Shire has announced that interim chief financial officer James Bowling has resigned after ten years with the firm. Business • 20 Oct 14
AbbVie turns against $55 billion Shire acquisition AbbVie has pulled the plug on its plan to buy Shire, recommending shareholders vote against the planned $55 billion takeover following new US tax rules. Business • 16 Oct 14
AbbVie turns against $55 billion Shire acquisition AbbVie has pulled the plug on its plan to buy Shire, recommending shareholders vote against the planned $55 billion takeover following new US tax rules. Business • 16 Oct 14
Shire urges AbbVie to proceed with $54bn deal Shire Pharmaceuticals today urged AbbVie to proceed with its agreed $54-billion takeover. Business • 15 Oct 14
Shire urges AbbVie to proceed with $54bn deal Shire Pharmaceuticals today urged AbbVie to proceed with its agreed $54-billion takeover. Business • 15 Oct 14
Shire formally accepts AbbVie takeover offer Dublin-based Shire Pharmaceuticals has accepted a €40bn takeover bid from US giant AbbVie, the two companies have said. Business • 18 Jul 14
Shire formally accepts AbbVie takeover offer Dublin-based Shire Pharmaceuticals has accepted a €40bn takeover bid from US giant AbbVie, the two companies have said. Business • 18 Jul 14
Shire 'ready to accept' latest AbbVie bid Shire succumbed to an increased $53 billion takeover offer from AbbVie this morning, signalling the conclusion to a long-running courtship largely motivated by tax. Business • 14 Jul 14
Shire 'ready to accept' latest AbbVie bid Shire succumbed to an increased $53 billion takeover offer from AbbVie this morning, signalling the conclusion to a long-running courtship largely motivated by tax. Business • 14 Jul 14
AbbVie retracts comments in Shire takeover bid AbbVie has been forced to retract comments by its chief executive about shareholder support for its bid for Shire after being caught out by British takeover rules. Business • 09 Jul 14
AbbVie retracts comments in Shire takeover bid AbbVie has been forced to retract comments by its chief executive about shareholder support for its bid for Shire after being caught out by British takeover rules. Business • 09 Jul 14
